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Abstract
Cytotoxic CD8 T cells play important roles in eliminating infected and
transformed cells. Owing to their potential for therapeutic applications,
significant efforts are dedicated toward developing CD8 T cell–based vaccines.
Thus far, CD8 T-cell vaccination strategies have had limited success
therapeutically in contrast to those targeting antibody-based immunity.
However, if the current challenges and gaps in the understanding of T-cell
biology are overcome, the full potential of rational CD8 T-cell vaccine design
might be realized. Here, we review recent progress in this direction, focusing on
target selection and maintenance of function in the settings of chronic infections
and cancers.
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Introduction
Safe and effective vaccines have significantly reduced and even
eradicated many pathogen-related human health threats within
the past century1. Cancers and a handful of chronic viral infections remain the last frontier of prevention and treatment through
vaccination. Historically, the vast majority of vaccines have
focused on inducing humoral immunity, yet the remaining
immunological challenges may benefit from the engagement of
cell-mediated immunity as well2. In recent decades, large gains
have been made in the development of CD8 T cell–based
vaccines; however, complete protection in both pre- and postexposure cases has not yet been achieved. CD8 T-cell vaccine
development entails unique challenges that include (a) identifying and validating CD8 T-cell targets that correlate with protection and (b) maintaining and restoring optimal functionality
of CD8 T cells in an immunosuppressive or chronic infection
environment. This review focuses on CD8 T-cell responses to
vaccination and advances in these challenge areas from the past
few years and particularly on cancers and HIV chronic infection.
Promising directions for vaccine design include the identification of non-canonical CD8 T-cell targets and finding means of
sustaining CD8 T-cell function through the combination of
immunotherapy and inhibitor receptor blockade.

CD8 T-cell target recognition and identification
Unlike antibodies, which recognize conformational epitopes
exposed on the surfaces of proteins that have achieved
tertiary structure, CD8 T cells recognize 8–11 amino acid peptide
fragments displayed at the plasma membrane in complex with
major histocompatibility complex (MHC) class I molecules3,4.
In humans, MHC class I molecules are encoded at three human
leukocyte antigen (HLA) loci (A, B, and C). Peptide fragments arise primarily from standard protein degradation by the
multicatalytic proteasome and are further processed by peptidases in the cytosol or the endoplasmic reticulum where MHC
loading occurs5. Linear epitopes can be derived from any protein
domain, including buried internal regions. This is important
since, owing to cellular localization (for example, viral polymerases that are confined to the cytosol), not all pathogen- or
cancer-related proteins are accessible to antibodies but instead can
be detected by CD8 T cells. These target characteristics of CD8
T-cell epitopes offer a broader range of options for identifying an
infected or transformed cell and naturally complement humoral
immunity.
Epitope identification continues to be a largely empirical process. The two main methods of identifying T-cell targets are
mass spectrometry (MS) analysis and epitope mapping6,7.
The first approach isolates peptides from target cells and identifies them through MS. Thus, actively processed and displayed
peptides can be identified directly. Through this technique, posttranslationally modified or non-canonical peptides (for example,
spliced) can also be recognized8. Nevertheless, MS is resourceintensive and despite technical advances still requires large
amounts of starting material along with subsequent validation of
identified epitopes in a CD8 T cell–based assay. Despite gains
in sensitivity, the technique may not detect peptides displayed at
low levels that nevertheless can activate CD8 T cells.

Epitope mapping interrogates T-cell responses to a set of
synthetic peptides derived from the primary amino acid sequence
of pathogenic genomes7,9. Two main approaches have been used
for designing the peptide library: overlapping peptides or the
use of a predictive algorithm. Screening by either approach
becomes substantially more complex and cost-prohibitive the
larger the genome included in the analysis. Thus, the overlapping-peptide approach is best suited for individual proteins or
pathogens with small genomes and can be used with broad
applicability to probe T-cell responses across all MHC alleles. On
the other hand, use of a predictive algorithm allows for greater
coverage of a larger genome, since the library is designed for a
unique MHC allele binding pattern, thus restricting the number
of peptide candidates. Though rapidly evolving, current MHC
binding predictive algorithms remain imperfect and strongly
immunogenic epitopes can be missed. Overall, synthetic libraries
designed by either method require validation through a T-cell
recognition assay—typically enzyme-linked immunospot detection of gamma interferon—since not all of the predicted epitopes
are presented or produce an immunogenic response. More
importantly, non-linear epitopes or post-translational modifications cannot be accounted for by this process and can be entirely
unrepresented in conventional searches for T-cell epitopes.
Finally, only some of the epitopes identified and validated through
either method will turn out to be protective and further testing
will be required to assess their utility in context10.

New sources of cancer immunotherapeutic peptides
CD8 T-cell vaccine design for cancers requires the identification of tumor-specific epitopes and stimulation of robust and
effective CD8 T-cell responses against the epitope. Since tumors
are derived from a body’s own cells, many epitopes will arise
from self-antigens through over-expression of proteins in transformed cancer cells or display of antigens normally present
in immunopriviledged sites11. These antigens are typically
weak immunogens because of central and peripheral tolerance
mechanisms acting on the T-cell repertoire. However, tumor
cells can also give rise to neo-antigens through somatic mutations resulting in modified amino acid sequence or through
aberrant post-translational modifications (for example, hyperphosphorylation)11,12. Epitopes derived from neo-antigens have a
much greater potential for eliciting immunogenic responses
since they are not subject to central tolerance11. Although cancerinduced immunosuppression often stunts T-cell responses
against the tumor, inhibitory receptor therapy can help to restore
T-cell function, as discussed later in this review.
Large but still untapped sources of potentially immunogenic
neo-antigens are spliced peptides. The proteasome cleaves
proteins into linear peptide fragments; however, in 2004, it was
first reported that the proteasome can also splice together short
peptide fragments, typically from the same protein, resulting in
the formation of discontinuous epitopes13. The efficiency of the
mechanism through which this transpeptidation reaction takes
place is not well understood14–20; however, new data suggest that
spliced peptides are generated with the same efficiency as linear
epitopes21. At the same time, the frequency of spliced peptides
has been considered extremely rare, and only six cancer-related,
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spliced peptides have been identified in the past decade22.
However, using cutting-edge bioinformatics and liquid
chromatography–MS methods, a recent study determined that
a large fraction of class I ligands are, in fact, spliced proteasomal products23. By this new account, up to one third of protein
diversity is represented by spliced peptides, and these spliced
products account for one quarter of the total presented peptides,
uncovering a potentially large pool of untapped immunogenic
peptides that could be beneficial for targeting cancer cells23.
In addition, the first bacterial account of CD8 T-cell responses to
spliced epitopes has been reported in a Listeria monocytogenes
infection, expanding the applicability of spliced peptides to
infectious agents24. The authors used a combination approach
of in vivo and in silico predictive algorithm methods to identify
spliced peptides, creating a workflow that could be employed
in the future for spliced epitope identification. An important
area to investigate is the extent of splicing in transformed cells
compared with normal cells since the first spliced epitopes
discovered through low-throughput methods are all tumor
antigens. Lastly, since spliced epitopes are more frequent than
anticipated, vaccination platforms should take into consideration the use of whole antigens and maintenance of processing
requirements such as access to the proteasome.

Non-canonical presentation of HIV epitopes
HIV is a formidable challenge for many reasons. Owing to the
high variability and extensive glycosylation of the HIV envelope
protein, antibodies have been largely ineffectual in preventing
viral entry. CD8 T cells have been reported to help control viral
replication; however, high mutation rates allow for viral escape.
Another factor is T-cell exhaustion, a hallmark of chronic
infections, which is characterized by increased expression of
inhibitory receptors, loss of T-cell functions such as cytokine
production and cytotoxicity, and transcriptional and metabolic changes. Lastly, no identified epitope presented through
canonical MHC I presentation (on HLA-A, -B, and -C class I
molecules) has demonstrated complete protection from HIV.
Recent discoveries from the Picker lab point to non-canonical
epitopes presented on HLA-E molecules as a means of eliciting immunogenicity and protection25. HLA-E typically presents
a unique set of peptides, derived from the leader sequences of
classic MHC molecules. Their primary function is thought to
be the interaction with natural killer cells and their inhibitory
receptors NKG2 A-C in order to prevent cell lysis. Previously,
only a handful of pathogenic infections were shown to produce
CD8 T cells specific for HLA-E molecules loaded with peptides
that mimic leader sequences. Surprisingly, in 2016, HLA-E
molecules were reported to present simian immune deficiency
virus (SIV) peptides and elicit CD8+ T-cell responses depending on the virus immunization platform25. This phenotype is
specifically induced by a cytomegalovirus (CMV)-based vector
platform, which upregulates expression of the HLA-E molecule;
in contrast, pox vectors induced presentation of classic MHC I
molecules26. HLA-E–restricted CD8 T cells appear to carry out
the same functions in terms of cytotoxicity and cytokine release
as those that are classically induced through MHC I presentation.
Furthermore, CMV vaccine vectors, now known to induce
primarily HLA-E–restricted CD8 T cells, have been previously
shown to control and clear SIV infection in 50% of vaccinated

rhesus macaques27. The effects of CMV vaccine platforms on
CD8 T-cell development are reviewed in greater depth here28.
The use of HLA-E–restricted CD8 T cells is an appealing
approach because of naturally low polymorphism in the
human population and the potential for use of highly relevant,
established animal models. Hundreds of classic HLA A/B/C
alleles exist in the human population; of these, only the HLAB27 has been found to be associated with better virus replication control in HIV29 and also hepatitis C virus30. HLA-B27 is
present in only 6.1% of humans31. In contrast, HLA-E is
expressed in only two allelic forms, characterized by a single amino acid substitution32, and this difference has no impact
on peptide binding. In fact, the peptide binding groove is
conserved between humans and all species of macaques33. Furthermore, a 2017 study confirmed the conservation of HLA-E
expression levels, T-cell response patterns, and the ability to
present identical peptides between humans, rhesus macaques,
and cynomolgus macaques, which supports the establishment of
physiologically relevant animal models for HIV and SIV vaccine
platforms34. The applicability of this approach is now being
expanded to other pathogens since HLA-E–presented epitopes
have been recently discovered in a tuberculosis infection
setting through the use of in-depth MS26. One particular epitope
elicited immunodominant CD8 T-cell recall responses in 14 out
of 16 donors, further suggesting the broad applicability of HLAE–restricted T cells26. Many gaps remain in understanding how
antigen presentation is shifted from the classic MHC molecules
toward HLA-E through CMV vector vaccination and whether
HLA-E restriction or peptide specificity provides the protective advantage in an SIV setting. Nevertheless, HLA-E–restricted
CD8 T-cell responses are an exciting new direction because of
their broad applicability to a large patient population as well as
demonstrated protective capabilities.

Restoring and maintaining CD8 T-cell function
The presence of tumor-infiltrating lymphocytes, including
effector CD8 T cells, has been associated with better prognosis in a variety of cancers. However, CD8 T-cell function is frequently suppressed by the tumor microenvironment. A recently
established strategy for restoring T-cell function, especially in
cancer treatment, is checkpoint inhibitor blockade therapy35.
Inhibitory receptors, most prominently PD-1 and CTLA4,
are expressed on the CD8 T-cell surface upon activation and
interact with ligands expressed by antigen-presenting cells36.
While the main role of inhibitory receptors appears to be the
dampening of immune responses in order to prevent immunopathology, in a prolonged antigen exposure scenario, this ultimately
leads to CD8 T-cell dysfunction. So far, inhibitor blockade
therapy has produced remarkable results in clinical trials,
although only about 20% of patients respond to treatment36. Even
in responding patients, restoration of CD8 T-cell function is not
permanent and continuous immunotherapy is necessary36. Thus,
an essential question regarding T-cell dysfunction in cancer is
whether the process develops in the early stages of tumor
formation or whether it progresses gradually along with cancer
metastasis and further exposure to antigen. Understanding the
timing and molecular mechanisms of T-cell dysfunction can
redirect the development of CD8 T-cell vaccination strategies in
conjunction with checkpoint inhibitor therapy blockade.
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A recent study using a mouse model reports that T-cell dysfunction is initiated during the pre-malignancy phase, prior to tumor
formation and subsequent induction of an immunosuppressive
environment37. Thus, T-cell dysfunction is established early in
tumorigenesis and appears to be driven by persistent antigen
stimulation, analogous to the exhaustion scenario in a chronic
infection setting37. Inhibitor blockade was found to partially
alter the gene expression of tumor-specific dysfunctional T cells
but did not permanently re-shape the underlying epigenetic
landscape38. In support of this finding, a subsequent study characterized the changes in CD8 T-cell chromatin accessibility
that take place early in tumorigenesis39. Two distinct developmental phases were identified. Initially, epigenetic changes are
plastic and the CD8 T cells are amenable to reversal of the
dysfunction phenotype within the first week of tumor challenge
with inhibitor blockade treatment. However, prolonged antigen
exposure led to a fixed chromatin landscape characterized by
permanent dysfunction within a month of tumor implantation.
PD-1 high tumor-infiltrating lymphocytes from human melanoma
and non-small cell lung cancer biopsies were found to contain a mixture of reversible and irreversible chromatin states.
This suggests that a small population of CD8 T cells might still
be amenable to functional restoration and could provide a basis
for identifying patients who would be responsive to inhibitor
blockade therapy. It will become increasingly important to
understand the underlying differences between the two chromatin states and how to prevent transition to the fixed epigenetic
state for induction of de novo responses when formulating CD8
T-cell vaccines. Recent clinical trials have begun exploring
combination therapy of inhibitor blockade along with neoantigen–based CD8 T-cell vaccination. Since naïve T cells still
have the potential to develop into functional effector and
memory cells, this strategy may yield the best results yet. It will
be interesting to learn whether this combination prevents the
development of dysfunction in the CD8 T-cell compartment.
T-cell dysfunction characterized by inhibitor receptor
expression is a common feature in both cancer and chronic
infections. However, inhibitory receptor blockade therapy is used
much less prominently in the clinical setting of viral infections
(for example, HIV), even though these receptors have been
studied intensively in mouse models of T-cell exhaustion. Recent
reports suggest that, as with cancer, the exhaustion phenotype
originates in the early stages of the initial infection. In a mouse
model of chronic lymphocytic choriomeningitis virus (LCMV)
infection, PD-1 blockade temporarily restored the function
of exhausted T cells but failed to induce long-term functional
memory cells in the absence of treatment40. Exhausted T cells
were found to contain an inflexible epigenetic profile that was not
altered by PD-1 blockade. In addition, methylation of the PD-1
promoter in CD8 T cells, which promotes expression of the
inhibitory receptor, was found to occur early in the infection
time line and to be maintained in the long term41,42. Moreover,
PD-1 promoter methylation was shown to persist even in the
absence of antigen43. Much like in a cancer setting, inhibition
of PD-1-PD-L1/2 interactions does not reverse the epigenetic
changes44,45 and continuous therapy is likely necessary in order
to maintain T-cell function. However, restoration of the CD8
T-cell compartment with functional cells may still be possible.
In several murine studies, a subset of stem-like CXCR5+

memory follicular T cells, which retains a de-methylated
PD-1 promoter, was found to account for the proliferative burst
and repopulation of functional CD8 T cells after inhibitor
blockade therapy45–48. Moreover, inhibition of de novo DNA
methylation in naïve CD8 T cells through a conditional
knockout mouse model results in proper development and
functionality of the T-cell compartment, even under chronic
antigen stimulation conditions44. De novo T-cell priming in
conjunction with methylation inhibitors could be another
avenue for regenerating the CD8 T-cell compartment in a chronic
infection setting provided that specific, low-toxicity means of
inhibiting DNA methylation can be identified. More detailed
analyses of epigenetic changes affecting checkpoint inhibitor
genes have recently been summarized elsewhere36,49,50. Finally,
earlier findings about the synergistic effect of administering
combination therapy of PD-1 inhibitors along with the interleukin-2 (IL-2) cytokine, which improves the outcome of
chronic LCMV infection over inhibitory therapy alone, might be
re-examined from an epigenetic viewpoint. This combination
therapy produced a large expansion of antigen-specific CD8
T-cells, further characterized by decreased surface expression
of PD-1 and an increase in the memory T-cell markers IL-7Rα
and the transcription factor T-bet and, resulted in a higher
responsiveness to PD-1 blockade treatment51. It would be
interesting to examine the methylation state of the PD-1
promoter in these CD8 T-cells in order to determine whether
the epigenetic landscape associated with exhaustion has been
reversed.

Concluding remarks
CD8 T-cell vaccine development against cancers and chronic
infections have common challenges. In both cases, although
antigen-specific CD8 T cells can be elicited through vaccination,
this does not translate into long-term protection. To overcome
this, both re-evaluation of T-cell vaccine targets and devising
methods for the maintenance of functionality are likely necessary. A promising trend redirects attention to non-conventional
CD8 T-cell epitopes, such as spliced non-linear peptides, and
the non-canonical antigen presentation molecule HLA-E.
Improved target selection can be further supported by vaccination platforms that include checkpoint inhibitor blockade therapy
since maintenance of CD8 T-cell function in prolonged disease
states is a fundamental problem. Lastly, a better understanding of the mechanisms behind T-cell dysfunction and checkpoint
inhibitors should lead to effective treatment in a wider segment
of the cancer patient population but also in chronic infection
settings.
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